In considering this possibility, we note that although every cell in patients with CE harbours an EPOR truncation, therapeutic deployment of the genome-editing strategy will result in the introduction of tEPOR in only a subset of HSPCs resident in the BM. The gene discussed is EPOR; the disease is cholesteryl ester measurement.